Literature DB >> 30692215

Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity.

Ole Audun Werner Haabeth1,2,3, Timothy R Blake4, Colin J McKinlay4, Anders A Tveita2,3, Adrienne Sallets1, Robert M Waymouth4, Paul A Wender4,5, Ronald Levy6.   

Abstract

Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing additional tumors throughout the body. In this study, to evoke systemic antitumor responses, we utilized charge-altering releasable transporters (CART) for local intratumoral delivery of mRNA coding for costimulatory and immune-modulating factors. Intratumoral injection of the CART-mRNA complexes resulted in mRNA expression at the site of administration, transfecting a substantial proportion of tumor-infiltrating dendritic cells, macrophages, and T cells in addition to the tumor cells, resulting in a local antitumor effect. Using a two-tumor model, we further show that mRNA therapy locally administered to one tumor stimulated a systemic antitumor response, curing both tumors. The combination of Ox40l-, Cd80-, and Cd86-encoding mRNA resulted in the local upregulation of proinflammatory cytokines, robust local T-cell activation, and migration of immune cells to local draining lymph node or to an anatomically distant tumor. This approach delayed tumor growth, facilitated tumor regression, and cured tumors in both A20 and CT26 tumor models. These results highlight mRNA-CART therapy as a viable approach to induce systemic antitumor immunity from a single localized injection. SIGNIFICANCE: The mRNA-CART system is a highly effective delivery platform for delivering immunostimulatory genes into the tumor microenvironment for potential therapeutic development. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30692215      PMCID: PMC6445668          DOI: 10.1158/0008-5472.CAN-18-2867

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Multi-emissive difluoroboron dibenzoylmethane polylactide exhibiting intense fluorescence and oxygen-sensitive room-temperature phosphorescence.

Authors:  Guoqing Zhang; Jianbin Chen; Sarah J Payne; Steven E Kooi; J N Demas; Cassandra L Fraser
Journal:  J Am Chem Soc       Date:  2007-07-04       Impact factor: 15.419

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 3.  Non viral vectors in gene therapy- an overview.

Authors:  Murali Ramamoorth; Aparna Narvekar
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 4.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

5.  Producer cells of interleukin-12.

Authors:  G Trinchieri; M Rengaraju; A D'Andrea; N M Valiante; M Kubin; M Aste; J Chehimi
Journal:  Immunol Today       Date:  1993-05

Review 6.  Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

Authors:  Elisa González-Rodríguez; Delvys Rodríguez-Abreu
Journal:  Oncologist       Date:  2016-06-15

7.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

8.  Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).

Authors:  U M Sarmiento; J H Riley; P A Knaack; J M Lipman; J M Becker; M K Gately; R Chizzonite; T D Anderson
Journal:  Lab Invest       Date:  1994-12       Impact factor: 5.662

9.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

10.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

Authors:  G J Freeman; F Borriello; R J Hodes; H Reiser; J G Gribben; J W Ng; J Kim; J M Goldberg; K Hathcock; G Laszlo
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Intratumoral Immunotherapy for Early-stage Solid Tumors.

Authors:  Wan Xing Hong; Sarah Haebe; Andrew S Lee; C Benedikt Westphalen; Jeffrey A Norton; Wen Jiang; Ronald Levy
Journal:  Clin Cancer Res       Date:  2020-02-18       Impact factor: 12.531

2.  Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.

Authors:  Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish
Journal:  Blood Adv       Date:  2020-09-08

3.  Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful.

Authors:  Izabela Szulc-Kielbik; Michal Kielbik
Journal:  Exp Suppl       Date:  2022

Review 4.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

5.  Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect.

Authors:  Patrick A Ott
Journal:  Cancer Cell       Date:  2021-11-08       Impact factor: 38.585

6.  Homogeneous polyporus polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor microenvironment.

Authors:  Wenyu Jia; Siwan Luo; Gena Lai; Shiqi Li; Shuai Huo; Meifang Li; Xing Zeng
Journal:  BMC Complement Med Ther       Date:  2021-05-25

Review 7.  Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.

Authors:  Clément Anfray; Aldo Ummarino; Fernando Torres Andón; Paola Allavena
Journal:  Cells       Date:  2019-12-23       Impact factor: 6.600

Review 8.  mRNA in cancer immunotherapy: beyond a source of antigen.

Authors:  Karine Breckpot; Sandra Van Lint; Lien Van Hoecke; Rein Verbeke; Heleen Dewitte; Ine Lentacker; Karim Vermaelen
Journal:  Mol Cancer       Date:  2021-03-03       Impact factor: 27.401

Review 9.  Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy.

Authors:  Maria L Guevara; Francesca Persano; Stefano Persano
Journal:  Front Chem       Date:  2020-10-23       Impact factor: 5.221

10.  An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.

Authors:  Ole A W Haabeth; Julian J K Lohmeyer; Adrienne Sallets; Timothy R Blake; Idit Sagiv-Barfi; Debra K Czerwinski; Blaine McCarthy; Abigail E Powell; Paul A Wender; Robert M Waymouth; Ronald Levy
Journal:  ACS Cent Sci       Date:  2021-06-18       Impact factor: 14.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.